BLATOPICALGEL
Approved
Dec 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
3/8 — Basic
NEXOBRID (anacaulase-bcdb) by MediWound is eschar. First approved in 2022.
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEXOBRID is a topical gel containing anacaulase-BCDB approved for eschar removal in burn wounds. The exact mechanism of action remains incompletely characterized, though the product works through enzymatic debridement. It represents a novel approach to wound care in severely burned patients.
Peak
Product is at peak commercial stage with moderate competitive pressure (30), indicating stable revenue potential and ongoing cross-functional team engagement.
Mechanism of Action
eschar. The specific components responsible for this effect have not been identified.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
A Study to Evaluate the Efficacy and Safety of NexoBrid in Subjects With Thermal Burns
Started May 2015
175 enrolled
Thermal Burns
A Study to Evaluate the Efficacy and Safety of NexoBrid in Children With Thermal Burns Compared the Standard of Care
Started May 2015
145 enrolled
Thermal Burns
Use of NexoBrid for Treatment of Acute Deep Partial and Full Thickness Burn Injuries
Thermal Burn
Career Relevance
Working on NEXOBRID offers highly specialized technical career opportunities, particularly in IT/Automation systems supporting manufacturing and supply chain operations. The niche market and manufacturing complexity create demand for specialized technical expertise rather than broad commercial roles.
Worked on NEXOBRID at MediWound? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.